ATE499356T1 - 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1 - Google Patents

6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1

Info

Publication number
ATE499356T1
ATE499356T1 AT05790292T AT05790292T ATE499356T1 AT E499356 T1 ATE499356 T1 AT E499356T1 AT 05790292 T AT05790292 T AT 05790292T AT 05790292 T AT05790292 T AT 05790292T AT E499356 T1 ATE499356 T1 AT E499356T1
Authority
AT
Austria
Prior art keywords
pyridinyl
inhibitors
protein kinase
tau protein
pyrimidone derivatives
Prior art date
Application number
AT05790292T
Other languages
English (en)
Inventor
Kazutoshi Watanabe
Kenji Fukunaga
Toshiyuki Kohara
Fumiaki Uehara
Shinsuke Hiki
Satoshi Yokoshima
Original Assignee
Mitsubishi Tanabe Pharma Corp
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Sanofi Aventis filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE499356T1 publication Critical patent/ATE499356T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05790292T 2004-09-29 2005-09-29 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1 ATE499356T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004313115 2004-09-29
PCT/JP2005/018497 WO2006036015A2 (en) 2004-09-29 2005-09-29 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors

Publications (1)

Publication Number Publication Date
ATE499356T1 true ATE499356T1 (de) 2011-03-15

Family

ID=35848411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05790292T ATE499356T1 (de) 2004-09-29 2005-09-29 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1

Country Status (25)

Country Link
US (1) US8129377B2 (de)
EP (3) EP1805164B9 (de)
JP (1) JP5186213B2 (de)
KR (1) KR20070057931A (de)
CN (1) CN101048397A (de)
AR (1) AR051823A1 (de)
AT (1) ATE499356T1 (de)
AU (1) AU2005288045B2 (de)
BR (1) BRPI0515851A (de)
CA (1) CA2581179A1 (de)
CY (1) CY1112326T1 (de)
DE (1) DE602005026546D1 (de)
DK (1) DK1805164T3 (de)
EA (1) EA013004B1 (de)
ES (1) ES2359071T3 (de)
IL (1) IL182223A0 (de)
MX (1) MX2007003722A (de)
NO (1) NO20072214L (de)
NZ (1) NZ554722A (de)
PL (1) PL1805164T3 (de)
PT (1) PT1805164E (de)
SI (1) SI1805164T1 (de)
TW (1) TWI354669B (de)
WO (1) WO2006036015A2 (de)
ZA (1) ZA200703383B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
WO2008023239A1 (en) * 2006-08-23 2008-02-28 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
TW201446748A (zh) 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
MX2010002765A (es) 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2464632A1 (de) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidonderivate als tau-proteinkinase-1-hemmer
WO2011062194A1 (ja) 2009-11-18 2011-05-26 武田薬品工業株式会社 アミノピリジン誘導体
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
NZ602110A (en) 2010-02-18 2014-09-26 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2928473B1 (de) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselektive n-2-arylierung von indazolen
SG11201909807TA (en) 2017-04-24 2019-11-28 Tesaro Inc Methods of manufacturing of niraparib
CN111138412B (zh) * 2018-11-06 2023-09-15 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
BR112023005387A2 (pt) * 2020-10-06 2023-04-25 De Shaw Res Llc Compostos lactam como bloqueadores de canais agitadores de potássio kv1.3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1136482A1 (de) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer
EP1136483A1 (de) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidonderivate
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
NZ531637A (en) 2001-09-21 2005-12-23 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives as tau protein kinase 1 inhibitor
EP1454908B1 (de) * 2003-03-07 2008-02-27 Sanofi-Aventis Substituierte Pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinonderivate
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
JP2008514587A (ja) 2008-05-08
CY1112326T1 (el) 2015-12-09
EA200700756A1 (ru) 2007-10-26
PT1805164E (pt) 2011-04-11
CA2581179A1 (en) 2006-04-06
EP1805164B1 (de) 2011-02-23
EP2261224A2 (de) 2010-12-15
EP2266969A3 (de) 2011-02-16
CN101048397A (zh) 2007-10-03
NZ554722A (en) 2010-07-30
JP5186213B2 (ja) 2013-04-17
ZA200703383B (en) 2009-05-27
ES2359071T3 (es) 2011-05-18
DK1805164T3 (da) 2011-05-16
EA013004B1 (ru) 2010-02-26
AU2005288045A2 (en) 2008-05-29
US8129377B2 (en) 2012-03-06
BRPI0515851A (pt) 2008-08-12
WO2006036015A2 (en) 2006-04-06
KR20070057931A (ko) 2007-06-07
DE602005026546D1 (de) 2011-04-07
EP1805164B9 (de) 2011-09-07
EP1805164A2 (de) 2007-07-11
PL1805164T3 (pl) 2011-07-29
NO20072214L (no) 2007-06-12
AU2005288045A1 (en) 2006-04-06
EP2266969A2 (de) 2010-12-29
AR051823A1 (es) 2007-02-14
TW200626573A (en) 2006-08-01
IL182223A0 (en) 2007-09-20
MX2007003722A (es) 2007-05-23
EP2261224A3 (de) 2011-02-16
TWI354669B (en) 2011-12-21
WO2006036015A3 (en) 2006-06-01
US20090239864A1 (en) 2009-09-24
SI1805164T1 (sl) 2011-05-31
AU2005288045B2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
ATE499356T1 (de) 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE412652T1 (de) Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE505460T1 (de) Indazolderivate als inhibitoren der hormon- sensitiven lipase
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
DE602005008079D1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE602005025363D1 (de) Substituierte amide als inhibitoren der beta-sekretase
ATE496029T1 (de) Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE388148T1 (de) Chinolinderivate als phosphodiesterase inhibitoren
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
ATE374201T1 (de) 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
DK1811998T3 (da) Triazoler anvendelige som inhibitorer af proteinkinaser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1805164

Country of ref document: EP